Year 8, Number 31, January 2006

 

Oncología
Article N°AJ31-11

 

 


Noguera, E.; Palazzo, E.; Terlecki, A.; Borello, A.; Mayoraz, M.; Garcia, J.; Sturich, G.; Soria, A.

División of Nuclear Medicine and Oncology. Hospital Privado de Córdoba, Argentina. e-Mail ENOGUERA@HOSPITALPRIVADOSA.COM.AR

Cita/Reference:
Noguera, E.; Palazzo, E.; Terlecki,A. et al. Comparison between scintigraphy with 99mTc cisteine-glucosamine and gallium 67 for the evaluation of patients with Hodgkin’s Disease. Preliminary observations. Alasbimn Journal (31): January 2006.



Comparison between scintigraphy with 99mTc cisteine-glucosamine and gallium 67 for the evaluation of patients with Hodgkin’s Disease. Preliminary observations


Radionuclide imaging of lymphoma with Gallium-67(67Ga) is a well establish procedure. However 67Ga scan has some limitations (is not readily available at Nuclear Medicine Labs, tumor imaging and interpretation should be delayed until 3-7 days postinyection, low spatial resolution and high cost). 99mTc labelled agents could be used as an alternative to 67Ga. Glucosamine (G) is a six-carbon amino sugar, enters the cells by a glucose transporter system and by phosphate and glycolitic pathways forms glucosamine-6-phosphate, is promising as an oncologic imaging agent. Reacting G with cysteine (C) has been labeled with 99mTc (99mTc-CG). This agent has been evaluated in patients with different types of cancer to show hypermetabolic lesions.

Objective: Comparison of 99mTc-CG and 67Ga in patients with Hodgkin’s disease(HD) in different stages of disease.

 Materials and Methods: 27 consecutive patients (8 M, 19 F; age range 14 – 72 years) with histopathologic diagnosis of HD were studied with 99mTc-CG and 67Ga. All patients underwent whole body scan and SPECT(reconstructed with OSEM algorithm) on the field of view of the lesion, with 1) 99mTc-CG (patients fasted for 12 hrs, dose: 1088MBq, imaging 1 and 4 hrs after injection). To eliminate the intravascular and interstitial activity of SPECT images, patients were given 737 MBq of 99mTc human serum albumin(99mTc-HSA) and other SPECT was done. Both SPECT were normalize and subsequently the 99mTc-HSA image was subtracted from the 99mTc-CG imaging, 2) 67Ga (inyection of 220MBq and imaging done after 3-4 days). 26 patients had histology of nodular sclerosis and one mixed cellularity. Patients were classified as active HD (n=17) or in complete remission (n=10) according to the clinical stage of the disease(CSD) (defined by physical examination, laboratory values, lymph node biopsy, Chest X-Ray and Computerized Axial Tomography of the neck, chest,and abdomen).99mTc-CG and 67Ga scans were defined as positive in the presence of uptake unrelated to the normal biodistribucion of both isotopes.

Results: In patienst with active HD, images with 99mTc-CG were positive in all sites showing abnormal 67Ga uptake. All patients with HD in remission showed negative images with both 99mTc-CG and 67Ga. Considering CSD as the reference standard we found that the sensitivity and specificity of 99mTc-CG was 100%. No false positive images were visualized. Only two patients (11%) with active HD who completed chemotherapy were imaged again with both agents 3 weeks later. In both patients the images were negative.

Conclusion: Scintigraphy with 99mTc-CG is a good alternative to 67Ga for evaluating patients with active and in remission of HD. Compared with 67Ga, <99mTc-CG can be done in one day and also is less expensive. Image subtraction is helpful in highlight tumoral uptake.

 


Centellograma con 99mTc MIBI sensibilizado con dobutamina en pacientes portadores de melanoma: resultados preliminares | Comparison between scintigraphy with 99mTc cisteine-glucosamine and gallium 67 for the evaluation of patients with Hodgkin’s Disease. Preliminary observations | Scintigraphic sentinel node detection in breast cancer patients: paired and blinded comparison of Dextran500-99mTc and Phytate-99mTc | Detección del Ganglio Centinela en Estadios iniciales del Carcinoma de Cervix | Localización de Ganglio Centinela en Cáncer de Mama: Comparación de Tc99m- Nanocoloide versus Tc99m- Dextran. | Efectividad del PET-FDG en la caracterización del nódulo pulmonar solitario: estudio multicéntrico internacional | Valor predictivo de la Tomografía de Emisión de Positrones [18F]- Fluoro-Deoxy-Glucosa (PET-FDG) como marcador precoz de la respuesta terapéutica en pacientes con cáncer de mama localmente avanzado tratadas con quimioterapia neoadyuvante | PET FDG en Patología Gineco-Oncológica. Experiencia Chilena | Tomografía de Emisión de Positrones (PET-CT) en la Pesquisa de Cáncer en Individuos Voluntarios Sanos | A propósito de 1000 casos de estudios metabólicos con PET flúor - deoxiglucosa en Chile | Print

 

 

Sitio desarrollado por SISIB - Universidad de Chile